Financial Analysis: Sensei Biotherapeutics (NASDAQ:SNSE) & Cynata Therapeutics (OTCMKTS:CYYNF)

Cynata Therapeutics (OTCMKTS:CYYNF) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, earnings, dividends and institutional ownership.

Analyst Recommendations

This is a summary of current ratings for Cynata Therapeutics and Sensei Biotherapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cynata Therapeutics	0	0	0	0	0.00
Sensei Biotherapeutics	1	1	1	1	2.50

Sensei Biotherapeutics has a consensus target price of $55.00, suggesting a potential upside of 373.73%. Given Sensei Biotherapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Sensei Biotherapeutics is more favorable than Cynata Therapeutics.

Institutional and Insider Ownership

10.5% of Sensei Biotherapeutics shares are held by institutional investors. 23.2% of Sensei Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Cynata Therapeutics has a beta of -0.36, suggesting that its stock price is 136% less volatile than the S&P 500. Comparatively, Sensei Biotherapeutics has a beta of 0.28, suggesting that its stock price is 72% less volatile than the S&P 500.

Profitability

This table compares Cynata Therapeutics and Sensei Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cynata Therapeutics	N/A	N/A	N/A
Sensei Biotherapeutics	N/A	-76.85%	-64.86%

Valuation and Earnings

This table compares Cynata Therapeutics and Sensei Biotherapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cynata Therapeutics	N/A	N/A	N/A	N/A	N/A
Sensei Biotherapeutics	N/A	N/A	-$30.16 million	($19.13)	-0.61

Summary

Sensei Biotherapeutics beats Cynata Therapeutics on 7 of the 9 factors compared between the two stocks.

About Cynata Therapeutics

Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops CYP-004, which is in Phase III clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds. In addition, the company develops products for the treatment of asthma, heart attack, coronary artery disease, brain cancer, sepsis, acute respiratory distress syndrome, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Cynata Therapeutics Limited has a strategic partnership with Fujifilm to provide clinical and commercial manufacturing services for, and supply of, Cynata's Cymerus therapeutic mesenchymal stem cell products. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.